Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6

US6235281A · kind A · utility

Assignee

• Knoll, Inc. · DE

Inventors

• Roswitha Stenzel · Lampertheim, DE
• Martin Kaul · Neustadt, DE
• Lothar Daum · Otterstadt, DE
• Joachim Kempeni · Neustadt, DE
• Christa Raab · Schifferstadt, DE
• Sibylle Schaefer · Walldorf, DE

Key dates

• Filing date: Aug 7, 1996
• Grant date: May 22, 2001
• Expiry date: Aug 7, 2016

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of TNF antagonists for producing drugs for the treatment of disorders characterized by elevated serum levels of interleukin-6.